“However, whether it is a newer innovation in imaging, dialysis therapy, mechanical ventilation or circulatory support, nothing has really moved the needle in terms of improved clinical outcomes. These are mainly supportive care technologies that keep the patient alive until they can recover on their own,” said Halpern.
Continue reading
“Our collaboration with CytoSorbents enables us to offer this innovative, easy-to-use blood purification therapy to address our customers’ most challenging cardiac cases,” stated Arik Anderson, President of Perfusion and Surgical Devices Division at Terumo. “CytoSorb integrates with the heart-lung machine platform, giving surgical teams, for the first time, the ability to safely reduce dangerous inflammatory mediators in real-time as they are being generated during cardiac surgery.”
Continue reading
2020 was a year like no other. Since March 2020 conferences and events have rightfully been cancelled or postponed across the world, including our Annual International CytoSorb Users Meeting. So we challenged ourselves to come up with something that could to some extend replace the live event.
Continue reading
According to the current definition, sepsis is a life-threatening organ dysfunction due to a dysregulated body response to an infection. This systemic infection can be caused by bacteria, fungi or even viruses.
Continue reading
In this study, clinical researchers at Maasstad Hospital and at Erasmus University Medical Center in Rotterdam, Netherlands conducted a retrospective evaluation of 116 patients with septic shock, who required vasopressors to increase their blood pressure, and renal replacement therapy (RRT) due to kidney failure.
Continue reading
Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, „I am happy to announce CytoSorbents successfully completed its CE Mark and ISO13485:2016 re-certification audits. These certificates cover CytoSorb and our new manufacturing facility commissioned in June 2018. The success of this renewal of the CE Mark and recent audit is a reflection of CytoSorbents‘ ongoing commitment to quality. I am very proud of our quality, manufacturing, and research teams that contributed to these accomplishments.“
Continue reading
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, expands CytoSorb distribution to Brazil, Colombia and Costa Rica, with Contatti Medical, Service & Medical Colombia, and Nutricare Costa Rica, respectively.
Continue reading
One day ahead of the 39th International Symposium of Intensive Care and Emergency Medicine (ISICEM), CytoSorbents invited for its 6th International CytoSorb Users Meeting at the Square Meeting Center in Brussels, Belgium.
Continue reading
On the eve of the 18th DIVI 2018 in Leipzig, CytoSorbents invited to the 5th German-speaking CytoSorb user meeting. An excellent speaker panel presented in Leipzig new data and insights on the following topics …
Continue reading
Blood poisoning is one of the leading causes of death in Germany. The Bramscher Niels Stensen clinics are now working as one of the first homes in the region with a new method that helps fight blood poisoning as early as possible and save human lives.
Continue reading